Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study.

Portman DJ, Brown L, Yuan J, Kissling R, Kingsberg SA.

J Sex Med. 2017 Jun;14(6):834-842. doi: 10.1016/j.jsxm.2017.03.258.

2.

Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.

Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ.

Womens Health (Lond). 2016 Jun;12(3):325-37. doi: 10.2217/whe-2016-0018. Epub 2016 May 16.

3.

To the Editor.

Portman DJ, Archer DF, Martel C, Labrie F.

Menopause. 2016 Apr;23(4):471-2. doi: 10.1097/GME.0000000000000638. No abstract available.

PMID:
26908208
4.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.

Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; VVA Prasterone Research Group.

Menopause. 2016 Mar;23(3):243-56. doi: 10.1097/GME.0000000000000571.

PMID:
26731686
5.

Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.

Bouchard C, Labrie F, Derogatis L, Girard G, Ayotte N, Gallagher J, Cusan L, Archer DF, Portman D, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E; VVA Prasterone Group.

Horm Mol Biol Clin Investig. 2016 Mar;25(3):181-90. doi: 10.1515/hmbci-2015-0044.

6.

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.

Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; Members of the VVA Prasterone Research Group.

J Sex Med. 2015 Dec;12(12):2401-12. doi: 10.1111/jsm.13045. Epub 2015 Nov 23.

PMID:
26597311
7.

Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.

Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dubé R; other participating members of VVA Prasterone Group.

Menopause. 2015 Dec;22(12):1289-95. doi: 10.1097/GME.0000000000000470.

PMID:
25968836
8.

One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy.

Portman D, Shulman L, Yeaw J, Zeng S, Uzoigwe C, Maamari R, Iyer NN.

Menopause. 2015 Nov;22(11):1197-203. doi: 10.1097/GME.0000000000000465.

PMID:
25944522
9.

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.

Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É; Members of the VVA Prasterone Group.

Maturitas. 2015 May;81(1):46-56. doi: 10.1016/j.maturitas.2015.02.005. Epub 2015 Feb 16.

PMID:
25771041
10.

Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).

Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J; VVA Prasterone Group.

Menopause. 2015 Sep;22(9):950-63. doi: 10.1097/GME.0000000000000428.

PMID:
25734980
11.

Incremental direct and indirect costs of untreated vasomotor symptoms.

Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM.

Menopause. 2015 Mar;22(3):260-6. doi: 10.1097/GME.0000000000000320.

PMID:
25714236
12.

New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.

Kaunitz AM, Portman D, Westhoff CL, Mishell DR Jr, Archer DF, Foegh M.

Contraception. 2015 Mar;91(3):211-6. doi: 10.1016/j.contraception.2014.11.013. Epub 2014 Nov 25.

PMID:
25586864
13.

Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.

Kaunitz AM, Portman D, Westhoff CL, Archer DF, Mishell DR Jr, Foegh M.

Contraception. 2015 Mar;91(3):204-10. doi: 10.1016/j.contraception.2014.11.011. Epub 2014 Nov 25.

PMID:
25582984
14.

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.

Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel.

Menopause. 2014 Oct;21(10):1063-8. doi: 10.1097/GME.0000000000000329.

PMID:
25160739
15.

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.

Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel.

J Sex Med. 2014 Dec;11(12):2865-72. doi: 10.1111/jsm.12686. Epub 2014 Aug 25.

PMID:
25155380
16.

In reply.

Kaunitz AM, Portman D, Westhoff CL, Archer DF, Mishell DR Jr, Foegh M.

Obstet Gynecol. 2014 May;123(5):1108. doi: 10.1097/AOG.0000000000000248. No abstract available.

PMID:
24785870
17.

Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.

Portman DJ, Kaunitz AM, Howard B, Weiss H, Hsieh J, Ricciotti N.

Contraception. 2014 Apr;89(4):299-306. doi: 10.1016/j.contraception.2014.01.013. Epub 2014 Jan 29.

18.

Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.

Portman DJ, Kaunitz AM, Kazempour K, Mekonnen H, Bhaskar S, Lippman J.

Menopause. 2014 Oct;21(10):1082-90. doi: 10.1097/GME.0000000000000210.

19.

Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.

Simon J, Portman D, Mabey RG Jr; Ospemifene Study Group.

Maturitas. 2014 Mar;77(3):274-81. doi: 10.1016/j.maturitas.2013.12.005. Epub 2013 Dec 17.

20.

Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.

Kaunitz AM, Portman D, Westhoff CL, Archer DF, Mishell DR Jr, Rubin A, Foegh M.

Obstet Gynecol. 2014 Feb;123(2 Pt 1):295-303. doi: 10.1097/AOG.0000000000000095.

PMID:
24402597

Supplemental Content

Loading ...
Support Center